In Brief: Andexanet alfa (Andexxa) Withdrawn
Abstract
Andexanet alfa (Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto), has voluntarily been withdrawn from the market.1 Andexxa was the only drug FDA-approved for this indication in the US.
Fields of Study & Subjects
Atrial Fibrillation Management and Outcomes
Chemical Reactions and Isotopes
Venous Thromboembolism Diagnosis and Management
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1746
- Pages
- 16–16
- Publication date
- 19 January 2026
- Language
- EN